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Abstract
Background: The success of the clinical use of sequencing based tests (from single gene to genomes) depends on
the accuracy and consistency of variant interpretation. Aiming to improve the interpretation process through
practice guidelines, the American College of Medical Genetics and Genomics (ACMG) and the Association for
Molecular Pathology (AMP) have published standards and guidelines for the interpretation of sequence variants.
However, manual application of the guidelines is tedious and prone to human error. Web-based tools and software
systems may not only address this problem but also document reasoning and supporting evidence, thus enabling
transparency of evidence-based reasoning and resolution of discordant interpretations.
Results: In this report, we describe the design, implementation, and initial testing of the Clinical Genome Resource
(ClinGen) Pathogenicity Calculator, a configurable system and web service for the assessment of pathogenicity of
Mendelian germline sequence variants. The system allows users to enter the applicable ACMG/AMP-style evidence
tags for a specific allele with links to supporting data for each tag and generate guideline-based pathogenicity
assessment for the allele. Through automation and comprehensive documentation of evidence codes, the system
facilitates more accurate application of the ACMG/AMP guidelines, improves standardization in variant classification,
and facilitates collaborative resolution of discordances. The rules of reasoning are configurable with gene-specific or
disease-specific guideline variations (e.g. cardiomyopathy-specific frequency thresholds and functional assays). The
software is modular, equipped with robust application program interfaces (APIs), and available under a free open
source license and as a cloud-hosted web service, thus facilitating both stand-alone use and integration with
existing variant curation and interpretation systems. The Pathogenicity Calculator is accessible at http://calculator.
clinicalgenome.org.
Conclusions: By enabling evidence-based reasoning about the pathogenicity of genetic variants and by
documenting supporting evidence, the Calculator contributes toward the creation of a knowledge commons and
more accurate interpretation of sequence variants in research and clinical care.
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Background
Successful clinical diagnostic application of exome and
genome sequencing hinges on the ability of clinical labora-
tories to consistently and accurately assess pathogenicity
of genetic variants. Several studies have identified incon-
sistencies in variant classification across laboratories,
reference databases, and even within individual databases
[1–4]. Interpretation requires the use of professional
judgment and non-standardized evidence types, thus it is
unrealistic to expect interpretation concordance of all
variants across all laboratories and data sources. However,
it is anticipated that knowledge sharing, standardization of
best practices, and transparent documentation of evidence-
based reasoning will have significant positive impact on
both consistency and accuracy.
To improve the standardization of variant interpretation
by clinical testing laboratories, the American College of
Medical Genetics (ACMG) and the Association of
Molecular Pathologists (AMP) have recently updated
guidelines for the interpretation of sequence variants [5].
The new guidelines provide significantly more information
about the types and weight of evidence used to classify
variants compared to the prior guidelines [6]. Overall, they
define 28 different evidence codes capturing different
types of evidence for or against pathogenicity of a variant,
only a subset of codes typically being applicable for a
specific variant. There are 20 rules for combining the
evidence codes for a given variant in order to reach
one of five conclusions about pathogenicity (Patho-
genic, Likely Pathogenic, Uncertain Significance, Likely
Benign, or Benign).
The formal structuring of evidence-based arguments
for or against pathogenicity and their implementation in
software provide several opportunities for enhancing the
emerging knowledge of genetic variation. One such op-
portunity is efficient evidence tracking that facilitates
critical evaluation of variant classifications. Recent stud-
ies [1, 4] suggests that a framework for organizing and
communicating evidential support and the reasoning
behind specific assessments of variant pathogenicity
facilitates resolution of inter-laboratory discordances.
However, currently available software systems and web
services provide only rudimentary support for guideline-
based reasoning [7] and do not facilitate full evidence
tracking or collaborative resolution of discordances.
They also do not enable guideline configuration to meet
ACMG guideline specification and customization for
specific genes and diseases, nor integration with existing
variant curation systems. We here address these gaps by
describing the design, development, and application of
the ClinGen Pathogenicity Calculator, thus fostering the
improvement of clinical classification of variants, a key




The Calculator client-side, including the main interface,
is implemented using JavaScript and ExtJS. The main
Calculator interface (Fig. 1) presents variant assessment
information within four vertically stacked panels. The
top panel displays information available in the ClinGen
Allele Registry for the variant being classified plus links
to additional information about the variant in key exter-
nal resources. The second panel provides an assessment
summary of the current user plus any other assessment
summaries for the same variant that are shared within
collaborating groups or publicly available. In this panel,
one may either initiate a new assessment by creating a
new blank evidence document (assessment record) or
browse available assessments by clicking on the appro-
priate tab. The third panel provides a summary of
ACMG/AMP guideline rules that are satisfied to draw a
classification based on the evidence tags that were pro-
vided for this variant in the evidence document, with
each evidence tag corresponding to an evidence code.
The last panel provides a summary of evidence tags that
were provided, each displayed within one cell of the
evidence grid. The cell for each tag is determined by the
strength of tag evidence for or against pathogenicity
(grid columns) and by tag evidence type (grid rows). The
Calculator also provides alternate classifications that
could be possibly satisfied in the middle panel and in the
lower panel the evidence code(s) that would be needed
to reach this classification. This latter feature may aid
groups doing variant classification to identify what type
of additional data could be sought (or shared) in order
to reach a conclusion (as illustrated in Additional file 1:
Figure S1).
Allele registration and data linking
As illustrated in Additional file 2: Figure S2, the
Calculator utilizes the services of the ClinGen Allele
Registry to identify a unique variant and collates
information about it from external sources to aid in
classification. The registry accepts wide variety of
Human Genome Variation Society (HGVS) recom-
mended expressions for substitution, insertion, deletion,
and indels [9]. It also supports query using HUGO Gene
Nomenclature Committee (HGNC) gene identifiers. If
an allele is not present in the Registry, the Calculator
may register the new allele within seconds upon request
by an authenticated user. More information about the
ClinGen Allele Registry is available at http://reg.clinical-
genome.org (manuscript in preparation).
The registry enables linking and viewing of pathogen-
icity assessments that are independently generated by
different users (displayed under different tabs in the
second panel in Fig. 1) as well as linking of relevant
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external supporting information about the variant. The
current set of externally linked information includes
ClinVar [10], dbSNP [11], dbNSFP [12], COSMIC [13],
ExAC [14], and myvariant.info [15].
Modeling and storage of semi-quantitative guidelines and
assessments
For the purpose of modeling and storing configurable
semi-quantitative guidelines and assessments for individ-
ual variants, the Calculator utilizes GenboreeKB, a
system for document-oriented modeling and storage.
The information is stored within four document collec-
tions within GenboreeKB. The first two collections store
semi-quantitative guidelines such as the ACMG/AMP
guidelines using one document collection for guideline
rules and metarules and another for evidence codes. The
third document collection defines the cell (row and
column) for each evidence tag within the evidence
grid (fourth panel in Fig. 1 or alternatively Fig. 1d).
The fourth document collection stores the complete
pathogenicity assessment information for individual
variants.
The reasoning engine
One core module of the Pathogenicity Calculator is a
generic reasoner written in the R programming lan-
guage. The reasoner takes the guidelines (defined using
rules, metarules, and evidence tags) and aggregated
Fig. 1 Four-panel interface for the ClinGen Pathogenicity Calculator
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evidence for the variant being pathogenic or benign
(encoded as a set of evidence tags) and produces a
conclusion (Fig. 1). The reasoner provides documenta-
tion of reasoning for each conclusion and identifies con-
clusions that are a few evidence tags away from being
satisfied. The output of the reasoner is a JSON docu-
ment that is used by the Pathogenicity Calculator inter-
face to display the conclusion, the evidence codes, and
any other conclusions that are close to being reached.
Support for collaboration
GenboreeKB is implemented in Ruby as an enhance-
ment to the Genboree server. Thus, the group-based
data sharing is managed by the Genboree access control
system. A web-based GenboreeKB management inter-
face employing the ExtJS Javascript framework is avail-
able as a plugin of the Redmine Rails (www.redmine.org)
application.
Data modeling, storage, and application program
interfaces
GenboreeKB utilizes MongoDB for data storage and
exposes in an access-controlled way. The complete data
contents of a Calculator is exposed as JSON via
Genboree REST HTTP application program interfaces
(APIs). GenboreeKB stores both data models and the
data itself as document collections and exposes them
via the APIs.
Integration with existing variant curation and evaluation
tools and systems
Numerous tools and systems for variant curation and
evaluation have been developed and used by various
laboratories. Recognizing that some of those tools may
benefit from the functionalities of the Calculator, all the
data and functionality of the Calculator are programmat-
ically accessible via REST APIs. The Calculator may be
used as a web service (with authentication and collab-
orative features such as group-based access control) or
by installing it on local hardware.
Results
The original ACMG/AMP guidelines can be translated into
an algorithm with only modest adaptations
Two adaptations of the original guidelines had to be in-
troduced to facilitate formal algorithmic reasoning. First,
several metarules were introduced to capture implicit
“common sense” rules practitioners were expected to
apply without explicit instruction. For example, if there
are two strong and three moderate-strength evidence
tags in favor of pathogenicity, then the variant can be
pathogenic (≥2 strong evidence tag) or likely pathogenic
(≥3 moderate-strength evidence tags). In such a case the
metarules specify that the variant is pathogenic.
Conversely, evidence tags that can be combined to
yield both Likely Benign and Benign are scored as
Benign. The Calculator distinguishes between uncer-
tain significance that arises due to insufficient evi-
dence from uncertain significance due to conflicting
evidence.
Second, the guidelines allow the practitioners to
change the strength level originally assigned to certain
tags based on perceived strength of supporting data
for the tag (“To provide critical flexibility to variant
classification, some criteria listed as one weight can
be moved to another weight using professional judg-
ment, depending on the evidence collected,” from
[5]). To accommodate this flexibility within the for-
mal algorithmic reasoning system of the Calculator,
multiple new tags were defined for each original tag
where the new tags are identical except that their
evidence strength was formally redefined. For ex-
ample, the original “PVS1” tag constitutes “Very
Strong” evidence for pathogenicity while the newly
defined “PVS1-Strong” tag is defined as the same type
of evidence except that it constitutes only “Strong”
evidence for pathogenicity.
The calculator reduces human error when applying
variant assessment guidelines
The ACMG/AMP guidelines and the Calculator were
tested in the context of a multi-site study [1] involving
nine molecular diagnostic laboratories involved in the
Clinical Sequencing Exploratory Research (CSER) con-
sortium and 99 variants that were evaluated by multiple
laboratories who applied the ACMG/AMP rules. The
Calculator helped identify human error when these
groups applied the guidelines. The Calculator identified
that for 16 of 353 (5%) of the variant assessments, the
ACMG/AMP evidence codes listed by the participating
laboratory did not support the conclusion provided by
the laboratory; of these, nine (2.5%) of the 353 were
errors. The remaining seven were cases when the labs
used professional judgment to override the ACMG/
AMP rules.
A user may initiate a session by selecting a previously
created assessment from a list or by creating a new as-
sessment (user interfaces not shown). A new assessment
is initiated by providing an HGVS allele identifier (for
example, NM_000169.2:c.639 + 919G > A in the alpha
galactosidase gene, GLA) and condition name and mode
of inheritance (Fig. 2a). Using the services of the
ClinGen Allele Registry, the Calculator identifies the
allele by a canonical identifier (“CA021883” in the top
panel) and, if the allele is not present in the registry, pro-
vides an option to register the new allele within seconds.
Upon registration, all future assessments of the same
allele become linked via the canonical identifier, thus
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enabling the sharing of assessments among users and
between the users and any automated assessment pipe-
lines. Shared assessments appear under different tabs in
the second panel (Fig. 1) where one may also initiate a
new assessment by creating a new blank evidence docu-
ment (assessment record).
The user can then add evidence tags using one of two
available interfaces. A click on an individual cell in Panel
4 activates a new panel where one or more tags that
belong to that cell may be applied (Fig. 2b). A user may
enter an optional free-text summary and may also asso-
ciate evidence tags with multiple links to supporting
data (Fig. 2c). Figure 2d shows a snapshot of a panel to
manage tags using an alternative interface. This panel
lists all possible tags for a selected type of variant inter-
pretation data (e.g. population, functional, etc.). This
interface is useful when the user does not know the
exact location of a tag within the evidence grid (fourth
panel in Fig. 1). Immediately upon addition or deletion
of a tag (using any of the two interfaces), conclusions in
the third panel (Fig. 1) are updated. The conclusions
reached based on current tag selection appear
highlighted at the top of this panel. A click on the icon
to the right of this conclusion highlights the columns in
the evidence grid (Additional file 1: Figure S1) that
contain supporting evidence for the conclusion. In
addition, potential conclusions that are close to being
reached are listed, together with the total number of tags
that need to be turned on for a conclusion to be reached.
A click on the icon to the right of such conclusions high-
lights the columns in the evidence grid where the missing
evidence tags reside (Additional file 1: Figure S1).
Fig. 2 a Interface for initializing an evidence document for a selected allele by adding information about disease condition and mode of
inheritance. b Interface for updating tags by clicking on a cell and selecting a tag from a pull-down menu. A link to a table defining tags in each
cell (such as a table with ACMG tags) is provided for reference. c Interface for updating links to supporting data for a tag by opening the “Manage
Links” tab in panel B and by entering one or more URLs/Links along with any free-text comments. d An alternate interface to manage tags and
provide summary and links. This interface lists all the tags for each evidence type (e.g. Population Data, Computational Data, etc.). This panel is
activated by clicking on the evidence type in the left-most column of the evidence summary table (Fig. 1, left-most column in the bottom panel)
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Advanced users (application developers) can access
the functionalities of the Calculator via Genboree REST-
APIs. Using the services, users can upload evidence tags
for several variants at a time. The uploaded data become
accessible through the interface as well as through
REST-APIs. In the future, the bulk upload functionality
will be made accessible even for regular users without
any background in computer programming.
The calculator facilitates critical evaluation of
pathogenicity assertions
Sharing of pathogenicity assessments of pathogenicity of
variants by clinical laboratories via databases such as Clin-
Var aids in the practice of clinical genome interpretation.
However, currently, the format of information by which
pathogenicity for a given variant was determined by mul-
tiple submitters to ClinVar often appears in a free text un-
structured format, if it is provided at all. It would be
useful if this knowledge sharing was further extended to
include the reasoning and evidence codes that supported
conclusions about pathogenicity in a standardized format.
For example, evidential support for an early assessment
that a variant is pathogenic may not have addressed more
recent information about the high frequency of the variant
in a specific population, thus explaining discordance with
a newer independent assessment that includes this recent
information. With the evidential support available for in-
spection, a user of the database may benefit from being
able to rapidly and critically evaluate both assessments
based on the evidence provided in a structured way. To-
ward this goal, the Calculator facilitates the sharing of the
reasoning and the evidential support behind every assess-
ment. Access to this information is provided via the inter-
faces (Fig. 1, Panel 3) and also via a single comprehensive
report that is also accessible via a URL and is printable as
a PDF (Fig. 3). The report (as PDF) may be included in
submissions to databases such as ClinVar or with Elec-
tronic Health Record (EHR) systems, thus enabling critical
evaluation of conclusions about pathogenicity. Although
the tool and underlying services are built in anticipation
of integration with EHR and other clinical information
systems by trained personnel, projects of this type have
not yet been initiated.
The calculator helps detect and resolve discordant
conclusions
Recent studies indicate that the initial application of the
ACMG/AMP guidelines did not increase concordance in
laboratory assessment [1]; however, it did help facilitate
resolution of the inter-laboratory discordances by
providing a framework for organizing and communicat-
ing evidential support behind independent assessments
of the same variant. To facilitate this process, the ability
of the Calculator to track the reasoning and evidence
discussed above is necessary but not sufficient. Two
more features are essential. First, independent assess-
ments of the same allele must be standardized, as differ-
ent labs/groups may be using different transcripts or
genome builds. This feature is accomplished through the
services of ClinGen Allele registry (top panel, Fig. 1).
Second, public or group-based sharing of assessments is
critical, which is accomplished by using group access
management features of the Genboree system. As a re-
sult, for each assessment for a given allele that is either
owned by a user or available to him/her for public or
group-based sharing, the user sees separate tabs in the
second panel (Fig. 1) of the Calculator. By clicking on
the tabs, the user may access complete information
about other assessments (in panels 3 and 4, Fig. 1, Add-
itional file 1: Figure S1 and Additional file 3: Figure S3).
This group-based comparison of variant interpretation
can also be used for proficiency testing challenges where
different sites can be asked to interpret the same variant.
The interpretation at the end of a challenge can then be
compared to evaluate the degree of overall concordance
and identify specific discordances.
The Calculator does not share information about patho-
genicity of variant publicly without explicit user request.
The information entered is protected using a login and
password. It provides optional free-text fields summariz-
ing tag assignments and links to supporting evidence. The
Calculator does not require or have fields for providing
identifying information about patients. Public sharing per
user request will be enabled in future releases.
The calculator guidelines are configurable without
programming to accommodate guideline evolution and
customizations for specific conditions
Although ACMG/AMP guidelines provide a general
framework for Mendelian sequence variant interpret-
ation, it was always recognized that this framework
would evolve and be customized to meet requirements
for specific genes and disease conditions [2, 16–19]. To
address these anticipated needs, the Calculator is de-
signed to support guideline evolution and customization
without programming. By using a lower-level Genbor-
eeKB interface (not shown), an “admin” user may fully
configure the Calculator by editing the following three
structured documents: (1) guideline rules and metarules;
(2) evidence codes and their assignments to the columns
and rows of the evidence grid (fourth panel in Fig. 1);
and (3) the rows and columns of the evidence grid itself.
These three documents completely define a formal
“guideline” used by the Calculator. Considering this
configurability, it is possible to customize the Calculator
for specific purposes (e.g. to implement guidelines for
somatic variant interpretation and/or multifactorial
inheritance).
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While each assessment refers to a specific guideline,
different guidelines may exist within the same system.
For example, for the purpose of assessing variants within
genes causing inborn errors of metabolism, metabolite
levels could be used as an evidence type in pathogenicity
assessments. Because the original ACMG/AMP guide-
lines do not specify this type of evidence or potentially
others that will be added in the future, we have designed
flexibility into the Calculator to allow for addition of
new evidence types (new rows in the evidence grid) and
corresponding evidence tags and of new rules without
programming.
Discussion
By automating the formal guideline-based assessment of
genetic variants, the ClinGen Pathogenicity Calculator
can reduce human error. The Calculator extends
functionality of other currently available calculators [7]
along several dimensions. First, it enables critical evalu-
ation of pathogenicity assessments by documenting the
complete reasoning from conclusions to relevant rules,
evidence tags and supporting data needed to reach a
more definitive conclusion (e.g. from likely pathogenic
to pathogenic; Additional file 1: Figure S1). Second, the
Calculator facilitates collaborative resolution of discor-
dances by linking multiple independent assessments of
the same variant and by enabling their group-based
sharing. Third, by being configurable, the Calculator
accommodates evolution of ACMG/AMP guidelines and
their customizations for specific genes and diseases [1,
16–18]. Fourth, the modular reasoning engine facilitates
integration of more quantitative guidelines such as those
Fig. 3 A sample summary report generated by Pathogenicity Calculator. The report itself is printable as PDF and downloadable by the user
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based on Bayesian inference that are used by the com-
munity for the assessment of some cancer predisposition
genes [20]. Finally, the Calculator supports program-
matic integration of rule-based reasoning into existing
variant interpretation and curation systems by providing
robust APIs implemented using free open source
software. Efforts are under way to integrate one or more
functionalities of the Calculator within the variant
curation interface that is under development by the
ClinGen Resource.
Conclusions
By providing an intuitive user interface and by addressing
other key computational requirements, the Calculator
facilitates formal and collaborative evidence-based reason-
ing about the pathogenicity of genetic variants, thus
paving the way toward more effective and accurate clinical
genomic interpretation.
Additional files
Additional file 1: Figure S1. A schematic showing a visual of evidence,
assertion, and reasoning for the user csersite6. The evidence, assertion,
and reasoning given in this panel is visible when the tab is switched
from Final (see Fig. 1) to csersite6. The “Supporting” and “Very Strong”
columns are highlighted after clicking on the top icon on the right of the
“Pathogenic” rule, indicating the type of evidence still required for the
rule to be satisfied and for the variant to be classified as “Pathogenic.”
(JPG 685 kb)
Additional file 2: Figure S2. Implementation of the ClinGen
Pathogenicity Calculator. A An abstract diagram showing inputs and
outputs. B Components of the Calculator, associated database, and web
services. The direction of arrows shows data flow and component
interactions. (JPG 2630 kb)
Additional file 3: Figure S3. A schematic showing a visual of evidence,
assertion, and reasoning for the user csersite3. The evidence, assertion,
and reasoning given in this panel is visible when the tab is switched
from Final (as in Fig. 1) to csersite3. (JPG 691 kb)
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